2020 ASCO Virtual Direct™ Highlights

 

Hematologic Oncology
10:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on AML: Does ENA+AZA Combo Improve Remission and ORR vs. AZA Mono? Is Addition of AZA to Ivo+Venetoclax Combo Well Tolerated?

FEATURING Robert Redner
  • 114 views
  • October 19, 2020
  • 1
02:50

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CP-CML: Does Changing Ponatinib Dose Result in Improved OS?

FEATURING Robert Redner
  • 9 views
  • October 19, 2020
11:15

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: How Safe Is AMG 330? Is the Addition of Pevonedistat to AZA Beneficial? What Is the Response Rate for Magrolimab+AZA Combo in TP53-Mutated Disease?

FEATURING Robert Redner
  • 45 views
  • October 19, 2020
07:22

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Multiple Myeloma: What Are the Response Rates With FDA-Approved Selinexor? Does KRd Offer Advantages vs. VRd?

FEATURING Robert Redner
  • 18 views
  • October 19, 2020
07:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on B-cell Lymphomas: Does Allogeneic anti-CD19 CAR-T Induce High Response Rates?

FEATURING Jakub Svoboda
  • 25 views
  • August 6, 2020
07:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Aggressive B‐Cell Lymphomas: Does Venetoclax Boost Benefits of R‐EPOCH?

FEATURING Jakub Svoboda
  • 452 views
  • August 6, 2020
  • 4
10:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CLL: Does Time‐limited Triplet Therapy (BOVen) Induce Rapid Undetectable MRD Responses in Untreated CLL?

FEATURING Jakub Svoboda
  • 273 views
  • August 6, 2020
09:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Multiple Myeloma: Should We Consider Idecabtagene Vicleucel, Anti-BCMA CAR-T Therapy, Effective in Heavily Pretreated R/R MM?

FEATURING Jakub Svoboda
  • 153 views
  • August 6, 2020
17:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R Indolent Lymphoma: Is Anti-CD19 CAR-T Axi-cel a Promising Therapeutic Approach for Patients With R/R iNHL?

FEATURING Jakub Svoboda
  • 116 views
  • August 6, 2020
  • 1
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Classical Hodgkin Lymphoma: Does Pembrolizumab Improve PFS vs. Brentuximab Vedotin in Patients With Relapsed/Refractory Disease?

FEATURING Jakub Svoboda
  • 140 views
  • August 6, 2020